Yeast-CEA vaccine clinical trials
Also written GI-6207.
- studies test it
- 14
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses yeast-CEA vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GI-6207
- 12
Studies by the year they started
14 studies that test it; most in 2018 (8)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 1 |
| 2017 | 4 |
| 2018 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 1
ImmunityBio, Inc. (12) · NantCell, Inc. (1) · National Cancer Institute (NCI) (1)
Often tested with
Tested in the same studies.
Nogapendekin alfa inbakicept (12) · ETBX-011 (12) · ETBX-051 (12) · ETBX-061 (12) · GI-6301 (12) · GI-4000 (11) · ETBX-021 (7) · Albumin-Bound Paclitaxel (1)
Studies
Open first, then newest update. How each study uses yeast-CEA vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169764Written as GI-6207How we know
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03175666Written as GI-6207How we know
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03563144Written as GI-6207How we know
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169738Written as GI-6207How we know
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03167177Written as GI-6207How we know
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnPhase 1/2ImmunityBio, Inc.NCT03169777Written as GI-6207How we know
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnPhase 1/2ImmunityBio, Inc.NCT03197571Written as GI-6207How we know
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnPhase 2ImmunityBio, Inc.NCT03554109Written as GI-6207How we know
- QUILT-3.080: NANT Pancreatic Cancer VaccineTerminatedPhase 1/2ImmunityBio, Inc.NCT03586869Written as GI-6207How we know
- QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.TerminatedPhase 1/2ImmunityBio, Inc.NCT03387085Written as GI-6207How we know
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/2ImmunityBio, Inc.NCT03387111Written as GI-6207How we know
- QUILT-3.006 for Recurrent Medullary Thyroid CancerCompletedPhase 2NantCell, Inc.NCT01856920Written as GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]How we know
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnPhase 1/2ImmunityBio, Inc.NCT03563170Written as GI-6207How we know
- An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...CompletedPhase 1National Cancer Institute (NCI)NCT00924092Written as GI-6207 [Recombinant Saccharomyces CerevisiaHow we know